Fox Run Management’s 10x Genomics TXG Stock Holding History

Fox Run Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-47,643	Closed	-$777K	–	1249
2025 Q4	$777K	Buy	47,643 +21,410	+82%	+$323K	0.12%	313
2025 Q3	$307K	Buy	+26,233	New	+$342K	0.05%	674
2025 Q2	–	Sell	-30,978	Closed	-$270K	–	1247
2025 Q1	$270K	Buy	+30,978	New	+$391K	0.04%	703
2024 Q4	–	Sell	-35,849	Closed	-$809K	–	1185
2024 Q3	$809K	Buy	+35,849	New	+$741K	0.18%	191
2024 Q2	–	Sell	-12,255	Closed	-$460K	–	1091
2024 Q1	$460K	Buy	+12,255	New	+$538K	0.1%	397
2023 Q4	–	Sell	-24,736	Closed	-$1.02M	–	1029
2023 Q3	$1.02M	Buy	24,736 +11,105	+81%	+$578K	0.3%	66
2023 Q2	$761K	Buy	+13,631	New	+$738K	0.21%	157
2021 Q1	–	Sell	-2,703	Closed	-$383K	–	318
2020 Q4	$383K	Buy	+2,703	New	+$392K	0.77%	21

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fox Run Management's TXG Position: Q1 2026 in Review

Fox Run Management sold out of 10x Genomics (TXG) in Q1 2026, closing a stake of 47,643 shares — an estimated $777K sold.

Fox Run Management first reported a position in TXG in Q4 2020 and held it in 8 quarters. The position peaked at $1.02M in Q3 2023. 331 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

Fox Run Management reported no remaining 10x Genomics position as of Q1 2026 after selling out during the quarter.
Fox Run Management sold 47,643 10x Genomics shares in Q1 2026, an estimated $777K.
Fox Run Management first reported a position in 10x Genomics in Q4 2020 and held it in 8 quarters.
Fox Run Management's 10x Genomics position peaked at $1.02M in Q3 2023.
331 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.